首页> 外文期刊>Papillomavirus Research >Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002–2012
【24h】

Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002–2012

机译:2002–2012年芬兰,在向青少年女孩引入人乳头瘤病毒(HPV)疫苗之前,发生了吉兰·巴雷(GBS),慢性疲劳/系统性运动耐力障碍疾病(CFS / SEID)和体位性体位性心动过速综合征(POTS)的发生率

获取原文
           

摘要

Background In Finland a vaccination programme against human papillomavirus (HPV) was introduced in November 2013 for girls aged 11–12 years with a catchup for girls 13–15 years. Allegations that HPV vaccine is causing Guillain Barré syndrome (GBS) and non-specific diagnostic entities, such as chronic fatigue syndrome/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS), continue to surface. We examined population register-based incidence rates of CFS/SEID, GBS and POTS to provide baseline data for future HPV vaccine safety evaluations. Methods First diagnosis of CFS/SEID, GBS and POTS in girls aged 11–15 years were obtained from the National Hospital Discharge Register during 2002–2012. We considered the following ICD-10 codes: G93.3 for CFS; G61.0 for GBS and G90.9, G90.8, G93.3, I49.8 for POTS. We calculated incidence rates per 100,000 person-years with 95% confidence intervals (CI). Results In total, 9 CFS/SEID, 19 GBS and 72 POTS cases were identified. The overall incidence rate was 0.53/100,000 (95% CI; 0.27–1.01) for CFS/SEID, 1.11 (95% CI; 0.71–1.74) for GBS and 4.21 (95%CI; 3.34–5.30) for POTS. Significant relative increase in annual incidence rate with a peak in 2012 was observed in CFS/SEID (33% (95% CI; 3.0–70.3: p=0.029) and POTS (16.5% (95% CI; 7.8–25.9: p0.05), but not in GBS (5.4% (95% CI; ?8.4–21.3: p=0.460). Conclusions Our findings provide baseline estimates of CFS/SEID, GBS and POTS incidences in Finland. However, rates based on register data should be interpreted with caution, especially for non-specific diagnostic entities for which internationally and even nationally agreed criteria are still being discussed. To assess the associations with HPV vaccine, methods using register linkage for cohort and self-controlled case series should be explored in addition to factors contributing to patients seeking care, treating physicians setting the diagnoses, and their preference of using of codes for these clinical entities. Highlights ? CFS/SEID, GBS and POTS can be found in all distinct age- and sex-related diagnostic entities. ? Significant increase in CFS/SEID and POTS but not in GBS rates in years before HPV immunization. ? Rates based on register data should be interpreted with caution, especially for non-specific diagnostic entities. ? Factors contributing to clinicians setting the diagnoses and using different ICD-10 codes should be explored.
机译:背景技术芬兰于2013年11月推出了针对人乳头瘤病毒(HPV)的疫苗接种计划,该计划针对11至12岁的女孩,并追赶13至15岁的女孩。关于HPV疫苗正在引起格林巴利综合征(GBS)和非特异性诊断实体(例如慢性疲劳综合征/全身性运动耐受不良疾病(CFS / SEID)和体位性体位性心动过速综合征(POTS))的指控不断浮出水面。我们检查了基于人群登记的CFS / SEID,GBS和POTS发生率,为将来的HPV疫苗安全性评估提供了基线数据。方法2002-2012年间从国家医院出院登记册中获得11-15岁女孩的CFS / SEID,GBS和POTS的首次诊断。我们考虑了以下ICD-10代码:用于CFS的G93.3; GBS为G61.0,POTS为G90.9,G90.8,G93.3,I49.8。我们以95%的置信区间(CI)计算每100,000人年的发病率。结果共鉴定出9例CFS / SEID,19例GBS和72例POTS。 CFS / SEID的总发生率为0.53 / 100,000(95%CI; 0.27–1.01),GBS的总发生率为1.11(95%CI; 0.71–1.74),POTS的总发生率为4.21(95%CI; 3.34–5.30)。 CFS / SEID(33%(95%CI; 3.0–70.3:p = 0.029)和POTS(16.5%(95%CI; 7.8–25.9):p < 0.05,但在GBS中则没有(5.4%(95%CI;?8.4–21.3:p = 0.460)。结论我们的发现提供了芬兰CFS / SEID,GBS和POTS发病率的基线估计值。应谨慎解释,特别是对于仍在讨论国际乃至国家公认标准的非特异性诊断实体而言,要评估与HPV疫苗的关联性,应探索在人群和自我控制病例系列中使用注册链接的方法。除了有助于患者寻求治疗的因素,主治医生确定诊断的条件以及他们倾向于使用这些临床实体的代码外,其他所有与年龄和性别相关的诊断实体中都可以找到CFS / SEID,GBS和POTS 。?CFS / SEID和POT显着增加HPV免疫前几年中的S,但GBS率中没有。 ?基于寄存器数据的费率应谨慎解释,尤其是对于非特定诊断实体。 ?应该探讨有助于临床医生确定诊断并使用不同ICD-10代码的因素。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号